Quince Therapeutics completes Phase 3 NEAT trial enrollment, topline results expected in Q1 2026.

• Quince Therapeutics completes enrollment in Phase 3 NEAT trial for eDSP in A-T. • Topline results expected in Q1 2026. • Financing closed at a premium, increasing cash position to $35M. • Expected to last through Phase 3 topline results and Q2 2026. • Entered strategic relationship with Option Care Health for eDSP commercial launch. • eDSP is Quince Therapeutics' lead asset for A-T treatment.

Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company focused on rare diseases, has completed enrollment in its pivotal Phase 3 NEAT clinical trial evaluating its lead asset, encapsulated dexamethasone sodium phosphate (eDSP), for the treatment of Ataxia-Telangiectasia (A-T). The trial, known as NEAT (Neurological Effects of eDSP on Subjects with A-T), enrolled a total of 105 participants, including 83 participants in the primary analysis population aged six to nine years and 22 participants aged 10 years and older [1].

The company expects to report topline results from the Phase 3 NEAT clinical trial in the first quarter of 2026. Assuming positive study results, Quince plans to submit a New Drug Application (NDA) to the FDA in the second half of 2026 [2].

In addition to the clinical milestone, Quince has closed a financing round at a premium, increasing its cash position to approximately $35 million. This funding is expected to provide sufficient runway through the Phase 3 topline results and into the second quarter of 2026 [2].

Further solidifying its commercial development plans, Quince has entered into a strategic relationship with Option Care Health, Inc. (Nasdaq: OPCH), the nation's largest independent provider of home and ambulatory infusion services. This partnership aims to support the efficient launch of eDSP in the U.S. [1].

Quince Therapeutics remains confident in its ability to deliver topline results in the first quarter of 2026 and subsequent NDA submission in the second half of 2026, assuming positive study results. The company's eDSP System is designed to address a high unmet medical need for patients with A-T [2].

References:
[1] https://www.stocktitan.net/news/QNCX/quince-therapeutics-selects-option-care-health-as-specialty-infusion-l5aj9aw913of.html
[2] https://www.stocktitan.net/news/QNCX/quince-therapeutics-provides-business-update-and-reports-second-963u3lp7dxty.html